atopicDermatitis News & Analysis

AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug

AbbVie (ABBV) announced its acquisition of Apogee Therapeutics for $10.9 billion. The focus of this acquisition is Apogee's development of an experimental drug for atopic dermatitis, a type of eczema. This move is significant for AbbVie as it expands its portfolio in dermatological treatments. The transaction underscores the ongoing trend of consolidations in the biotech sector to enhance product pipelines.